Results 11 to 20 of about 735,101 (274)
Poor Performance Status Is Associated With Increased Mortality in Patients With Cirrhosis [PDF]
Clinical Gastroenterology and Hepatology, 2016 Functional status (a patient's ability to perform activities that meet basic needs, fulfill usual roles, and maintain health and well-being) has been linked to outcomes in patients with cirrhosis and can be measured by the Karnofsky performance status (KPS) scale.
Eric S Orman +2 more
exaly +5 more sources
Clinical Effectiveness of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with a Poor Performance Status [PDF]
Medicina, 2021 Immune checkpoint inhibitors (ICIs) are standard treatments for patients with lung cancer. PD-1/PD-L1 or CTLA4 antibodies are chosen as the first-line therapy, contributing to the long-term survival and tolerability.
Kyoichi Kaira +4 more
doaj +3 more sources
Outcome of treatment in patients with small cell lung cancer in poor performance status [PDF]
Acta Oncologica, 2019 Background: Patients with small cell lung cancer (SCLC) with poor performance status (PS) especially in the elderly may not benefit from chemotherapy. The aim of this study was to compare survival of treated patients with PS 3-4 with untreated patients.Material and methods: We reviewed the medical records and pathology data for 448 patients diagnosed ...
Rana Bahij +5 more
core +4 more sources
Prevalence of Poor Performance Status in Lung Cancer Patients: Implications for Research [PDF]
Journal of Thoracic Oncology, 2008 Performance status (PS) is a standard functional classification in oncology research and practice. However, despite its widespread use, little is known about the prevalence of poor PS in lung cancer patients, in relation to other cancers, based on the assessments of health care providers and patients.Data from two quality of life studies were pooled ...
Rogerio C Lilenbaum +2 more
exaly +3 more sources
Efficacy of Anamorelin in Advanced Pancreatic Cancer Patients with a Poor Performance Status. [PDF]
Intern MedObjective The efficacy of anamorelin in pancreatic cancer (PC) patients with a poor performance status (PS) is uncertain, as previous trials have excluded such patients. This study evaluated the efficacy of anamorelin in PC patients with a poor PS (2) compared with those with a good PS (0-1).
Takeda T +11 more
europepmc +3 more sources
Case Reports in Oncology, 2010 Introduction: Cetuximab-based chemotherapy showed a statistically significantly higher response rate compared with chemotherapy such as FOLFOX. Therefore, FOLFOX plus cetuximab is suspected to be the best regimen to alleviate tumor-related symptoms with ...
Kohei Shitara +7 more
doaj +2 more sources
Clinics, 2018 Patients with unresectable metastatic colorectal cancer live for a median of three years when treated with standard therapies. While the evidence guiding cancer-directed treatment of this disease comes from phase III trials that have mostly enrolled ...
Lucila Soares da Silva Rocha +1 more
doaj +2 more sources
Current Problems in Cancer: Case Reports, 2023 Targeted therapies are recommended for treatment of patients with non-small cell lung cancer (NSCLC) with actionable driver mutations, including those with poor performance status, who otherwise have limited treatment options.
Sebastian Kraus
doaj +2 more sources
Case Reports in Oncology, 2014 Patients with metastatic pancreatic adenocarcinoma and poor performance status (PS) are typically excluded from clinical trials of new systemic treatments.
Abdur R. Shakir
doaj +2 more sources
A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol [PDF]
BMC Cancer, 2022 Background Small-cell lung cancer (SCLC) accounts for 12–15% of lung cancers and has a limited prognosis, with approximately one-third of SCLC patients having a poor performance status (PS).
Tetsuhiko Asao +4 more
doaj +2 more sources